132
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Development of sustained release formulation of an antithrombotic drug and application of fuzzy logic

&
Pages 242-250 | Received 09 Aug 2010, Accepted 05 Oct 2010, Published online: 10 Nov 2010

References

  • Accessed from the website: http://en.wikipedia.org/wiki/Clopidogrel
  • Lenz TL, Wilson A. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Clin Pharmacokinet 2003;42:909–920.
  • Kam PCA, Nethery CM. The Thinopyridine derivatives (platel adenosine diphosphate receptor antagonist), pharmacology and clinical developments. Anaesthesia 2003;58:28–35.
  • Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metabolism Disposit 2002;30:1258–1295.
  • Herbert JM, Frechel D, Vallee E, Kieffer G, Gouy D, Berger Y. Clopidogrel, a novel antithrombotic agent. Cardiovasc Drug Rev 1993;11:180–198.
  • Mikatos A, Panderi I. Determination of the carboxylic acid metabolite of clopidogrel in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Analyt Chimica Acta 2004;505:107–114.
  • Accessed from the website: http://www.fda.Gov/Medwatch/safety/2004/Oct_PI/Plavix_PI.Pdf: (2006).
  • Mcewen J, Strauch G, Perle SP, Al E. Clopidogrel bioavailability is unaffected by food or antiacids. British Journal of Clinical Pharmacology 1996;36:856.
  • Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal 2002;28:431–438.
  • Garnier J, Cric S, Curry J, Morelli G, Arseneault A, Tanguay M. The single-dose pharmacokinetics of clopidogrel in healthy adult volunteers. Clin Pharmacol & Therapeutics 2003;73:2.
  • Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneim-Forsch/Drug Res 2004;54 No.9a:600–604.
  • Taubert D, Kastrati A, Bevkerath HV, Schomıg A, Schomıg E, Pogatsa-Murray G. Absorbption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation 2005;8:2946–2950.
  • Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC–MS/MS. J Pharmaceut Biomed Anal 2008;48:1219–1224.
  • Ki MH, Choi MH, Ahn KB, Kim BS, Im DS, Ahn SK, et al. The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. Arch Pharm Res 2008;31:250–258.
  • USPTO Patent Application #: 20070003628: Nanoparticulate clopidogrel formulations.
  • Podczeck F, Newton JM. Powder and capsule filling properties of lubricated granulated cellulose powder. Eur J Phar Biol 2000;50:373–377.
  • Picker-Freeyer KM, Brink D. Evaluation of powder and tableting properties of chitosan. AAPS Pharmscitech 2006;7(3):E1–10.
  • Schussele A, Bauer-Brandl A. Note on the measurement of flowability according to the European pharmacopoeia. İnt J Phar 2003;257:301–304.
  • Kumar V, Kothari SH, Banker GS. Compression, compaction, and disintegration properties of low crystallinity celluloses produced using different agitation rates during their regeneration from phosphoric acid solutions. AAPS Pharmscitech 2001;2(2):1–7.
  • Taubert D, Kastrati A, Harlfinger S, Gorchakva O, Lazar A, Bevkerath HV, et al. Pharmacokinetics of clopidogre after administration of a high loading dose. Thromb Haemost 2004;92:311–316.
  • Walsh P. Physicians’ Desk Reference (2005) Medical Economics Company, USA.
  • Mikatos A, Panderi I. A validated LC method for the determination of clopidogrel in pharmaceutical preparations. J Pharm Biomed Anal 2002;28:431–438.
  • Sproule BA, Naranja CA, Türksen IB. Fuzzy pharmacology: Theory and applications. Trends Pharmacolog Sci 2002;23(9):412–417.
  • Brier ME, Zurada JM, Aronoff GR. Neural network predicted peak and trough gentamicin concentrations. Pharm Res 1995;12:406–412.
  • Veng-Pedersen P, Modi NB. Application of neural networks to pharmacodynamics. J Pharm Sci 1993;82:918–926.
  • Huuskonen J, Salo M, Taskinen J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci 1997;86:450–454.
  • Bourquin J, Schmidli H, Van-Hoogevest P, Leuenberger H. Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development. Pharm Dev Technol 1997;2:95–109.
  • Baxt WG. Application of artificial neural networks to clinical medicine. Lancet 1995;346:1135–1138.
  • Bozic DZ, Vrecer F, Kozjek F. Optimization of diclofenac sodium dissolution from sustained release formulations using an artificial neural network. Eur J Phar Sci 1997;5:163–169.
  • Takahara J, Takayama K, Nagai T. Multi-objective simultaneous optimization technique based on an artificial neural network in sustained release formulations. J Cont Rel 1997;49:11–20.
  • Chen Y, McCall TW, Baichwal AR, Meyer MC. The applications of an artificial neural network and pharmacokinetics simulations in the designing of controlled-release dosage forms. J Cont Rel 1999;59:33–41.
  • Grau AJ, Reiners S, Lincy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke. Stroke 2003;April:849–855.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.